ASH 2022 | An update from BELLWAVE-001: nemtabrutinib in CLL/SLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, gives an update on the BELLWAVE-001 Phase I/II dose-expansion study (NCT03162536) of nemtabrutinib at the 65-mg dose in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Overall, the study reported that nemtabrutinib continued to show promising and durable antitumor activity with a tolerable safety profile in heavily pre-treated patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm Therapeutics: Research Funding; Schrodinger: Research Funding; Newave: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; ArQule: Consultancy; MorphoSys: Consultancy, Research Funding; Loxo@Lilly: Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy.
